Tag

Teva will pay $33.75 billion in cash and $6.75 billion in shares, representing a 10 percent stake in the Israel-based company, Teva said. Teva wants to bulk up its core generics business to help cope with stagnating drug prices and a decline in the supply of its raw material,...

Allergan ($AGN) has scooped up a med tech startup with an innovative treatment for dry eye disease, paying $125 million up front for the rights to a tiny device designed to spur tear production. The device, OD-01, has successfully treated symptoms of dry eye across four clinical...